![]() "But once that gets trued up, they're still setting pricing for a future period that most definitely is going to be at a higher cost than what it is right now. I know you don't like that, but I mean, most of the health plans are doing rebates because they did overshoot the mark on their premium rates," she said. "Current earnings are not necessarily an indicator of what future premium trends and profitability is going to be. "I find it hard, as someone who looks at the financial statements of the health plans, to figure out, given how much money they're making, why our premiums are going up so much," Nancy Turnbull, a board member who worked at the state's Division of Insurance before moving to the Harvard School of Public Health, said.īoard member Rina Vertes, a consultant who previously worked at health care and insurance companies, cited a decades-long difference of opinion with Turnbull and pointed out that the premiums that plans will charge next year aren't necessarily related to past financial performance. Martha Kwasnik, deputy general counsel at the Division of Insurance, said the primary drivers of the increases were increases in provider and pharmacy costs. The weighted average rate change for the individual and small group insurance market is a 6.6% premium hike, Adams said. The average change for the 140,055 people who get coverage through ConnectorCare silver tier plans is a 4.6% premium increase. Increases among carriers range from a 5.5% jump for Tufts Health Plan, the lowest, to an 11.9% hike for Health New England, the highest. ![]() Two dental carriers submitted 12 qualified dental plans for sale on the exchange, and Adams said those plans will see a 0.1% decrease in the premium. The average change to Health Connector premiums from 2022 to 2023 will be a 7.6% increase for the 85,474 members whose medical coverage is unsubsidized or who receive Advance Premium Tax Credits, Samuel Adams, a senior program analyst at the Health Connector, said. While the Health Connector approves the plans that it will offer for sale, the premium rates are filed with and reviewed by the Division of Insurance. The board's vote last Thursday gave a final seal of approval to eight insurance carriers that submitted a total of 45 non-group and 57 small group qualified health plans for coverage starting Jan. © 2023 by the American Diabetes Association.A year after cost increases that board members called "not sustainable" and "quite disappointing," there was no opposition last week as the Massachusetts Health Connector board approved plan offerings for 2023 that will lead some consumers who buy their health insurance through the exchange to pay an average of 7.6% more. In the current study we found increased risk of all thyroid cancer and medullary thyroid cancer with use of GLP-1 RA, in particular after 1-3 years of treatment. Use of GLP-1 RA for 1-3 years was associated with increased risk of all thyroid cancer (adjusted hazard ratio 1.58, 95% CI 1.27-1.95) and medullary thyroid cancer (adjusted HR 1.78, 95% CI 1.04-3.05). Risk of thyroid cancer related to use of GLP-1 RA was estimated with a conditional logistic regression with adjustment for goiter, hypothyroidism, hyperthyroidism, other antidiabetes drugs, and social deprivation index.Ī total of 2,562 case subjects with thyroid cancers were included in the study and matched with 45,184 control subjects. Case subjects were matched with up to 20 control subjects on age, sex, and length of diabetes with the risk-set sampling procedure. Exposure to GLP-1 RA was measured within the 6 years preceding a 6-month lag-time period and considered as current use and cumulative duration of use based on defined daily dose (≤1, 1 to 3, >3 years). All thyroid cancers were identified through hospital discharge diagnoses and medical procedures between 20. ![]() Individuals with type 2 diabetes treated with second-line antidiabetes drugs between 20 were included in the cohort. To determine whether use of glucagon-like peptide 1 (GLP-1) receptor agonists (RA) is associated with increased risk of thyroid cancer.Ī nested case-control analysis was performed with use of the French national health care insurance system (SNDS) database. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |